The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy
Australian Journal of Chemistry · 2022-02-22 · 75 (2) · 65-88
DOI: 10.1071/ch21184 ↗At a glance
Journal article in Australian Journal of Chemistry, published online on 2021-12-07. Written by Melyssa L. Grieve and 1 co-authors. Cited 29 times so far (Crossref); 197 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Several radiometals are of interest in the development of new a-emitting radiopharmaceuticals. This review highlights the role of coordination chemistry in the design of 225Ac, 212/213Bi, 212Pb, 149Tb, 227Th, and 223/224Ra radiopharmaceuticals to treat cancer. Several chelators have recently been developed that are addressing the specific requirements of each radiometal to provide outstanding radiolabelling and in vivo properties. These advances are supporting the momentum that is building around radiopharmaceuticals for targeted a therapy.
Cite
APA
Grieve, M. L., & Paterson, B. M. (2022). The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy. Australian Journal of Chemistry, 75(2), 65-88. https://doi.org/10.1071/ch21184
Vancouver
Grieve ML, Paterson BM. The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy. Australian Journal of Chemistry. 2022;75(2):65-88. doi:10.1071/ch21184
BibTeX
@article{Grieve2022,
author = {Grieve, Melyssa L. and Paterson, Brett M.},
title = {The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy},
journal = {Australian Journal of Chemistry},
year = {2022},
volume = {75},
number = {2},
pages = {65--88},
doi = {10.1071/ch21184}
}
EUVIMED